Patient Square Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.2M Buy
227,000
+90,500
+66% +$4.17M 2.34% 13
2025
Q4
$6.12M Buy
+136,500
New +$5.73M 1.31% 17

Other funds holding XENE

Patient Square Capital's XENE Position: Q1 2026 in Review

Patient Square Capital increased its Xenon Pharmaceuticals (XENE) stake by 66% in Q1 2026, buying an estimated $4.17M and bringing the position to 227,000 shares worth $13.2M. The position accounts for 2.34% of the portfolio, ranked #13.

Patient Square Capital first reported a position in XENE in Q4 2025 and has held it in 2 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Patient Square Capital held 227,000 shares of Xenon Pharmaceuticals worth $13.2M as of Q1 2026.
  • Patient Square Capital bought 90,500 Xenon Pharmaceuticals shares in Q1 2026, an estimated $4.17M.
  • Xenon Pharmaceuticals made up 2.34% of Patient Square Capital's portfolio in Q1 2026, its #13 holding.
  • Patient Square Capital first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Patient Square Capital's 13F filing for Q1 2026, filed 15 May 2026.